Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235391 · ClinicalTrials.gov registry record · Phase 3
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,683
- Enrollment target
NCT00235391 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,683 participants.
The verdict
NCT00235391, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,683 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
Interventions
- DRUG Deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,683 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235391
The ClinicalTrials.gov registry entry for NCT00235391 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,683 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox is the first listed.
NCT00235391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235391 about?
NCT00235391 is a clinical study titled "Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload". This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
What is the current status of trial NCT00235391?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,683 participants. The study started on 2005-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00235391?
The interventions under investigation include: Deferasirox (DRUG).
Who is sponsoring clinical trial NCT00235391?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.